Cerebellar tDCS + Language Therapy for Aphasia
(CeSAR Trial)
Trial Summary
You may need to stop taking certain medications, especially those that lower the seizure threshold or NMDA antagonists, as they are listed in the exclusion criteria.
Research shows that cathodal tDCS can improve language abilities in post-stroke aphasic patients, such as enhancing picture naming accuracy by 33.6%. Additionally, tDCS has been found to augment language outcomes in aphasia, suggesting it may be a useful tool when combined with language therapy.
12345Research on cathodal tDCS, including studies on post-stroke aphasia, suggests it is generally safe, with no serious adverse events reported during treatment sessions.
12467Cerebellar tDCS (transcranial direct current stimulation) combined with language therapy is unique because it targets the cerebellum, a part of the brain not traditionally associated with language, to enhance language recovery in aphasia patients. This approach is novel as it uses electrical stimulation to potentially improve language skills more effectively than standard language therapy alone, especially for untrained language tasks.
128910Eligibility Criteria
This trial is for English-speaking adults over 18 who had a stroke in the left hemisphere of their brain at least 6 months ago, resulting in aphasia and difficulty naming things. They must have been right-handed before the stroke. People with cerebellum damage, other neurological or psychiatric disorders, recent seizures, severe sensory loss, certain medication use, high baseline naming test scores, metal in their head or body implants are excluded.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 15 sessions of cerebellar tDCS combined with Semantic Feature Analysis (SFA) over 3-5 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment